• AM0010 is a pegylated recombinant form of human IL-10 (PEG-rHuIL-10) that is being developed for the treatment of cancer.
• PEG-IL-10 increases and activates intratumoral CD8+ T cells (Fig. 2) 3 .
• Intra-tumoral memory T cells correlate with survival in cancer patients 2 .
• In preclinical studies, PEG-IL-10 induces the rejection of large tumors and the development of immunological memory against the tumor cells (Fig. 4) .
STUDY OBJECTIVES Primary
• To assess the safety, tolerability, maximum tolerated dose (MTD), and pharmacokinetics (PK) of AM0010
Secondary
• To assess the tumor response • To evaluate anti-AM0010 antibodies
Exploratory Biomarkers
• Serum cytokines • T and B cell responses to tumor associated antigens • Immuno-profiling • Immuno-score
TRIAL DESIGN
• First-in-human, open-label, dose escalation study to evaluate the safety and tolerability of AM0010 in patients with advanced solid tumors dosed daily subcutaneously (SC) (clinicaltrials.gov identifier NCT02009449).
PATIENT ELIGIBILITY Major inclusion criteria
• Advanced solid tumors; limited to melanoma, prostate, ovarian, renal, colorectal, pancreas, non-small cell lung cancer
• Life expectancy of >16 weeks
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CONTACT INFORMATION
For more information on this trial, please contact martin.oft@armobio.com phone: 1-650-779-5075.
TRIAL STATUS
• This study is open for enrollment at 4 sites in the United States
• As of May 22, 2014 22 patients have been enrolled in the Dose Escalation phase.
• Enrollment in Cohort 4 (10 µg/kg) has been completed without the MTD being reached.
• 
Preclinical rationale
• PEG-IL-10 directly activates tumor specific CD8+ T cells.
• PEG-IL-10 increases IFN in the CD8+ T cell and MHC expression in the tumor.
• PEG-IL-10 induces tumor rejection and long lasting anti-tumor immune surveillance.
AM0010 / PEG-IL-10 Mechanism of Action
• Induces CD8+ T cell expansion via increased STAT3 phosphorylation (Fig. 2a,c) • Activates CD8+ T cell via STAT1 phosphorylation (Fig. 2c) • T cell activation increases Signal 2 via reduction of PD-1 expression • Induces IFN in CD8+ T cells (Fig. 2b) • 
ENDPOINTS
• Tumor Response will be assessed using the immune related response criteria (irRC) or the Prostate Cancer Working Group Criteria (PCWG2) for progression in bone
• Adverse Events will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.02) 
